BMYBristol-Myers SquibbRunning, no new patients
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 461 (final count)
- Started
- Nov 5, 2019
- Main results expected
- Jul 26, 2023
- Fully finished
- Jul 31, 2027
- Results posted
- Jul 23, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS) by BICR
Measured over: From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04025879 · record last updated 2026-08-26 · checked 2026-11-09 15:42 UTC